Generic Medicine Info
Indications and Dosage
Benign prostatic hyperplasia
Adult: 2.5 mg tid. Max: 10 mg/day. 1st dose should be given before bedtime. Extended-release: 10 mg once daily.
Elderly: Initially, 2.5 mg bid. Acute urinary retention: Extended-release: 10 mg once daily to be taken from 1st day of catheterisation. Duration: 3-4 days.
Renal Impairment
Initially, 2.5 mg bid. Adjust dose according to response.
Hepatic Impairment
Mild to moderate: Initially, 2.5 mg daily, may increase to 2.5 mg bid according to response. Severe: Contraindicated.
Should be taken with food.
Extended-Release: Should be taken with food. Take immediately after the same meal each day. Swallow whole, do not chew/crush.
History of orthostatic hypotension. Severe hepatic impairment. Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir).
Special Precautions
Prostatic carcinoma should be ruled out before starting therapy. Patient w/ acquired or congenital QT prolongation, prostate cancer, coronary artery disease, symptomatic hypotension. Renal and mild to moderate hepatic impairment. Not intended for use in women and childn. Pregnancy and lactation.
Adverse Reactions
Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, postural hypotension, tachycardia, angina pectoris in patient w/ pre-existing coronary artery disease, chest pain oedema, diarrhoea, upper resp tract infection, rhinitis, bronchitis, sinusitis, pharyngitis, hepatocellular and cholestatic liver injury including jaundice, dizziness, headache, fatigue, rash, pruritus, urticaria. Rarely, priapism can occur.
Patient Counseling Information
May impair ability to drive, operate machinery or perform hazardous tasks.
Monitoring Parameters
Monitor BP regularly and urine flow.
Symptoms: Hypotension. Management: Maintain patient in supine position to restore BP. IV fluids and/or vasopressors may be needed.
Drug Interactions
Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other α1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.
Potentially Fatal: Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) increase plasma alfuzosin levels.
Description: Alfuzosin is a quinazoline derivative which exhibits selectivity for α1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors causes relaxation of smooth muscle in the bladder neck and prostate, resulting in improvement in urine flow and a reduction in symptoms of benign prostatic hyperplasia (BPH).
Absorption: Readily absorbed. Bioavailability: Approx 64%. Time to peak plasma concentration: 0.5-3 hr.
Distribution: Plasma protein binding: 90%.
Metabolism: Extensively metabolised in the liver, mainly by the CYP3A4 isoenzyme, to inactive metabolites.
Excretion: In faeces via bile (69%) and via urine (24%; approx 11% as unchanged drug). Elimination half-life: 3-5 hr.
Store between 20-25°C. Protect from light and moisture.
MIMS Class
Drugs for Bladder & Prostate Disorders
Alfuzosin Hydrochloride Extended Release Tablet (Exelan Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/01/2014.

Anon. Alfuzosin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/01/2014.

Buckingham R (ed). Alfuzosin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 09/01/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Alfuzosin Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 09/01/2014.

Uroxatral (Concordia Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/01/2014.

Xatral 2.5 mg Film Coated Tablet (Aventis Pharma Limited). MHRA. Accessed 09/01/2014.

Disclaimer: This information is independently developed by MIMS based on Alfuzosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Profuzosin
  • RiteMED Alfuzosin HCl
  • Xatral OD
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in